HBM Healthcare Investments
🇨🇭XSWX.HBMNSwitzerlandFinancial Services
PriceCHF 230.00+2.00 (+0.88%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 3
- Medium: 6
- Low: 0
Debt to equity: rose sharply against the prior quarter
EBIT margin: collapsed against the prior period
Long-term debt to equity: a sudden spike above its trailing quarter average
Current ratio: below the level we flag as a liquidity warning
Net income: crossed zero, from positive to negative
Free with a Finzer account.
Profile
- Financial Services
- Asset Management
- Switzerland
Identity
- Exchange
- SIX Swiss Exchange . XSWX
- Type
- Stock
- ISIN
- CH0012627250
- CUSIP
- Not reported
Company
- Employees
- 0
- Headquarters
- Zug, Switzerland
Market
- Shares outstanding
- 6.6M
- Market cap
- CHF 1.52B
Highlights
- Market cap
- CHF 1.52B
- EPS LTM
- -CHF 21.89
- P/E LTM
- -10.51calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- 9.94%calculatedCalculated by Finzer, not reported by the data provider.
Fundamentals (LTM)
- Revenue
- -CHF 143.23M-475.32%down year on year
- Net income
- -CHF 147.01M-516.17%down year on year
- Gross margin
- 100.92%+20.81%up year on year
- Free cash flow
- -CHF 2.33M+1.73%up year on year
Latest news
News is not sourced for this exchange.
Business summary
HBM Healthcare Investments is a company in the financial services sector, listed on SIX Swiss Exchange (Switzerland) under the ticker HBMN. Its market capitalisation is CHF 1.52B, from 6.6M shares outstanding, as of . Across the 249 trading sessions to the shares traded between CHF 174.40 and CHF 258.00, and the last close of CHF 230.00 sits 67% of the way up that range. The company is headquartered in Zug, Switzerland.
HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies. The fund prefers to invest in start up, early stage, mid stage, mid venture, late venture, and late stage private companies, unlisted emerging companies, small cap public companies, buyouts, growth capital, and private investment in public equities (PIPES). Within fund of funds, it invests in venture capital funds. It also seeks to finance spin-offs of product lines or departments from larger corporations and the expansion or restructuring of established companies, seed stages, venture capital, expansion capital stages, spin-offs, and buyouts. The fund prefers to invest in the private and public companies in the healthcare sector with a focus on human medicine, drugs, pharma , biopharma, biotechnology, diagnostics, medical technology, and related industries. It seeks to make initial investments in companies whose primary products are in clinical development or the immediately preceding stage. The fund typically invests globally with a focus on Asia Pacific, Asia, North America, and Europe. In case of public companies, it focuses on those which originate from its private portfolio. The fund increases its investment in portfolio companies by participating in a follow-on financing or after the portfolio company's IPO. It may acquire majority participations in portfolio companies, usually takes a seat on the portfolio company's Board of Directors, and largely makes equity investments but may also invest through other instruments including convertible bonds, debt securities, structured products, and derivatives. The fund exits its portfolio companies through trade sale or IPO.